Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma

British Journal of Haematology
Ann Y MinnKaryn A Goodman

Abstract

The standard treatment for patients with refractory or relapsed Hodgkin lymphoma (HL) is high-dose chemotherapy and/or radiation with autologous haematopoietic cell rescue (AHCR). In this study, we assessed quality of life and evaluated the risk of late morbidity and mortality for HL patients who underwent AHCR. One hundred and fifty-four patients who underwent AHCR at Stanford University from 1988 to 2002 and survived ≥2 years were evaluated. Median follow-up was 10·2 years. There were 54 deaths, 34 from HL, 20 from other causes. The 10-year cumulative incidence of death from HL or other causes was 21·7% and 12·7%, respectively. Thirteen deaths were from second malignancies. The risk ratio of second malignancies was 8·0 [95% confidence interval (CI), 4·7-12·6] compared with the general population, and 3·0 (95% CI, 1·8-4·8) compared with HL patients not undergoing AHCR. The risk ratio of second malignancies was 1·5 (95% CI, 0·9-2·4) compared with HL patients receiving non-AHCR therapy. Overall quality of life did not differ from the general population, but AHCR survivors did note reduced functioning and some worse symptoms. AHCR survivors may be at increased risk of death from HL and other causes compared with the general popul...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·George P CanellosB A Peterson
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Jan 14, 1988·The New England Journal of Medicine·M A TuckerS A Rosenberg
May 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M B LundJ Boe
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Flora E van LeeuwenR Somers
Oct 27, 1993·JAMA : the Journal of the American Medical Association·S L HancockRichard T Hoppe
Jan 6, 1993·Journal of the National Cancer Institute·S L HancockRichard T Hoppe
Mar 21, 1996·The New England Journal of Medicine·S BhatiaA T Meadows
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M HudsonW M Crist
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J Johnston, S J Horning
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony J SwerdlowDavid C Linch
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R Schwarz, A Hinz
Feb 7, 2002·Journal of the National Cancer Institute·Lois B TravisEthel Gilbert
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea K NgP M Mauch
Jul 24, 2003·JAMA : the Journal of the American Medical Association·Lois B TravisEthel Gilbert
Mar 2, 2006·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeNational Comprehensive Cancer Network
Dec 8, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K Ng, P M Mauch
Feb 8, 2007·Journal of the National Cancer Institute·Anthony J SwerdlowDavid C Linch
Mar 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SirohiA Horwich
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karyn A GoodmanJoachim Yahalom

Citations

May 28, 2014·Annals of Hematology·Jorge LabradorRamón García-Sanz
Apr 17, 2013·Expert Opinion on Biological Therapy·Tiziana MoscatoMassimo Martino
Sep 9, 2015·Pediatric Transplantation·Volkan HazarTurkish Pediatric Bone Marrow Transplantation Study Group (TPBMT-SG)
Mar 17, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPaul A Carpenter
Jun 15, 2014·International Journal of Radiation Oncology, Biology, Physics·Bradford S HoppeNancy Mendenhall
Jun 21, 2014·Neuro-oncology·Jun WangPatrick B Johnston
Jul 31, 2016·Health and Quality of Life Outcomes·Nadine LinendollSusan K Parsons
Jul 2, 2020·OncoTargets and Therapy·Shinichi MakitaKensei Tobinai

Related Concepts

Antineoplastic Chemotherapy Protocols
Cause of Death
Combined Modality Therapy
Hodgkin Lymphoma, Lymphocyte Depletion
TNM Staging System
Quality of Life
Radiotherapy Dosage
Transplantation, Autologous
Second Primary Cancers
Hemopoietic Stem Cell Transplant

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Linda J Burns
The New England Journal of Medicine
S S Donaldson, S L Hancock
Australian and New Zealand Journal of Medicine
K R Horwood, H Samaratunga
International Journal of Radiation Oncology, Biology, Physics
Louis S ConstineNancy Mendenhall
© 2021 Meta ULC. All rights reserved